Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 150

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 150
---
 to receive for their investment
(i) two (2) shares of the Company’s common stock and (ii) one common stock purchase warrant to purchase an additional share of the
Company’s Common Stock exercisable for a three year period, at a per share exercise price of $2.40, at a per Unit price of $3.20
(the “Later Private Placement”; together with the Earlier Private Placement, the “2023 Private Placements”)).

NOTE 6 – STOCKHOLDERS’ EQUITY

The subscription
agreement with the investors with respect to the 2023 Private Placements provided that the subscription amounts may be utilized by the
Company only following the entry into by the Company or subsidiary thereof into an agreement whereby the Company would acquire research
services and/ or exclusive license or other rights with respect to technologies with multiple applications or into a business combination
with an entity that possesses research services and/ or exclusive license or other rights with respect to technologies with medical and
pharma applications. As such, upon receipt, the funds were classified as liability and recorded under other account payables.

<div align='center'>F-43</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 6 – STOCKHOLDERS’ EQUITY (Cont.)

The above condition
was satisfied by the entry by the Company into the share exchange agreement referred to in Note 1(b) on November 14, 2023. Accordingly,
following the execution of the share exchange agreement, the Company issued to the investors in respect of the 2023 Private Placements
an aggregate of 5,699,218 of the Company’s Common Stock and warrants to purchase an additional 2,849,609 shares of Common stock,
of which warrants for 1,437,500 shares have a per share exercise price of $0.80 and warrants for 1,412,109 shares have a per share exercise
price of $2.40. The warrants are exercisable through December 31, 2026.

Fund at the amount
of $50 which were received in escrow as an advance payment on account of shares were returned to the investor during the third quarter
of 2024 as the investor elected to not proceed with the investment. These funds were recorded under other accounts payables in Company's
consolidated balance sheets.

On November 6,
2023, the